文献速递乳腺癌

EndoPredict评分预测HR阳性HER2阴性乳腺癌新辅助化疗与内分泌治疗反应

The EndoPredict score predicts response to neoadjuvant chemotherapy and neoendocrine therapy in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients from the ABCSG-34 trial.
PubMed 文献 · Eur J Cancer · 2020-06-02

本研究基于ABCSG-34随机II期试验,对HR阳性HER2阴性早期乳腺癌患者进行12基因分子评分(EndoPredict)检测,评估其预测新辅助化疗(NaCT)或新辅助内分泌治疗(NET)后残余癌症负荷(RCB)的能力。结果显示,低评分患者对NaCT反应差(NPV 100%),高评分患者对NET反应差(NPV 92.3%),12基因评分可显著预测NaCT(AUC 0.736)和NET(AUC 0.726)的治疗反应。

要点

  • 低分子评分肿瘤不太可能从新辅助化疗中获益。
  • 高分子评分预测对新辅助内分泌治疗耐药。
  • 12基因评分可辅助HR阳性HER2阴性早期乳腺癌的个体化治疗选择。

核心结论

  • 12基因分子评分可预测HR阳性HER2阴性早期乳腺癌患者新辅助治疗后的残余癌症负荷。
  • 低评分肿瘤不太可能从新辅助化疗中获益,而高评分预测对新辅助内分泌治疗耐药。

研究设计与样本

  • 前瞻性转化研究,纳入ABCSG-34随机II期试验中HR阳性HER2阴性乳腺癌患者样本。
  • 进行EndoPredict检测生成12基因分子评分,根据绝经状态、HR表达、分级和Ki67分配接受NaCT或NET。
  • 疗效以残余癌症负荷(RCB)衡量。

主要发现

  • 接受NaCT的患者多数(125/134)12基因评分为高风险,接受NET的患者中低风险略多(44/83)。
  • 低风险NaCT治疗和高风险NET治疗的肿瘤反应差,NPV分别为100%(95%CI 66.4%-100%)和92.3%(95%CI 79.1%-98.4%)。
  • 12基因评分显著预测NaCT反应(AUC 0.736 [95%CI 0.63-0.84])和NET反应(AUC 0.726 [95%CI 0.60-0.85])。

关键数值与推荐

  • 低风险NaCT治疗的NPV为100%(95%CI 66.4%-100%)。
  • 高风险NET治疗的NPV为92.3%(95%CI 79.1%-98.4%)。
  • NaCT预测的AUC为0.736(95%CI 0.63-0.84)。
  • NET预测的AUC为0.726(95%CI 0.60-0.85)。

临床怎么用

  • 12基因分子评分可提供额外生物学信息,辅助HR阳性HER2阴性早期乳腺癌患者新辅助治疗的个体化选择。
  • 低评分患者可能避免新辅助化疗,高评分患者可能不宜选择新辅助内分泌治疗。
  • 该评分可作为新辅助治疗背景下生物标志物驱动研究的依据。

局限性

  • 研究基于ABCSG-34试验样本,样本量有限(NaCT组134例,NET组83例),结论需更大样本验证。
  • 研究为转化性分析,治疗分配非随机基于分子评分,可能存在选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Neoadjuvant chemotherapy (NaCT) and neoadjuvant endocrine therapy (NET) can reduce pre-operative tumour burden in patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative early-stage breast cancer. This prospective translational study assessed the ability of a 12-gene molecular score (MS; EndoPredict®) to predict response to NaCT or NET within the ABCSG-34 trial. PATIENTS AND METHODS: Hormone receptor (HR)-positive, HER2-negative samples from patients in the ABCSG-34 randomized phase II trial were selected and EndoPredict testing was performed to generate a 12-gene MS. ABCSG-34 patients were assigned to receive either NaCT or NET based on menopausal status, HR expression, grade and Ki67. Response was measured by residual cancer burden (RCB). RESULTS: Patients selected for NaCT generally had high-risk disease by 12-gene MS (125/134), while slightly more patients treated with NET had low-risk disease (44/83). Low-risk NaCT-treated and high-risk NET-treated tumours responded poorly (NPV 100% [95% CI 66.4%-100%] and NPV 92.3% [95% CI 79.1%-98.4%], respectively]. The 12-gene MS significantly predicted treatment response for NaCT (AUC 0.736 [95% CI 0.63-0.84]) and NET (AUC 0.726 [95% CI 0.60-0.85]). CONCLUSIONS: The 12-gene MS predicted RCB after treatment with neoadjuvant therapies for patients with HR-positive, HER2-negative early-stage breast cancer. Tumours with low MS were unlikely to benefit from NaCT, whereas a high MS predicted resistance to NET. This additional biologic information can aid personalized treatment selection in daily practice and builds a strong rationale to use EndoPredict in biomarker-driven studies in the neoadjuvant setting.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Dubsky PC, Singer CF, Egle D, et al. The EndoPredict score predicts response to neoadjuvant chemotherapy and neoendocrine therapy in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients from the ABCSG-34 trial. Eur J Cancer. 2020. PMID: 32502940. doi:10.1016/j.ejca.2020.04.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。